Fulgent Genetics Q1 2024 Adj EPS $(0.01) May Not Be Comparable To $(0.32) Estimate, Sales $64.485M Miss $65.363M Estimate
Fulgent Genetics Q1 2024 Adj EPS $(0.01) May Not Be Comparable To $(0.32) Estimate, Sales $64.485M Miss $65.363M Estimate
Fulgent Genetics 2024年第一季度調整後每股收益美元（0.01）可能無法與預期的美元（0.32）相提並論，銷售額爲6,4485萬美元未達到6,536.3萬美元的預期
Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.32) by 96.88 percent. This is a 95.45 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $64.485 million which missed the analyst consensus estimate of $65.363 million by 1.34 percent. This is a 2.54 percent decrease over sales of $66.168 million the same period last year.
Fulgent Genetics（納斯達克股票代碼：FLGT）公佈的季度虧損爲每股0.01美元，比分析師共識估計的美元（0.32美元）高出96.88％。這比去年同期每股虧損0.22美元（0.22美元）增長了95.45％。該公司公佈的季度銷售額爲6,4485萬美元，比分析師普遍預期的6536.3萬美元低1.34％。這比去年同期的6616.8萬美元的銷售額下降了2.54％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。